Conference Reports for NATAP

Back

9th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Sydney, Australia, July 19-21 2007     Dyslipidemia & Body Changes in Vertically Infected Children & Youth on PI ART: preliminary results of PACTG 1045 - (08/21/07)   Report from the 9th Intenational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney, Australia. July 19-21, 2007 - Written by Mike Dube - (08/16/07)   Lack of metabolic abnormalities and mitochondrial toxicity with enfuvirtide (T-20): a double-blind, placebo-controlled, crossover study with random sequence assignation in healthy adult volunteers - (08/14/07)   Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? - (08/13/07)   Lack of Association between Antiretroviral Therapy and Predictors of Endothelial Function and Cardiovascular Disease (CVD) Risk Among HIV-Infected Persons on Long-Term HAART pioglitazone increased limb fat, exercise reduced limb fat - (08/13/07)   Pioglitazone ± exercise training reduces liver lipid content and improves insulin sensitivity in HIV with impaired glucose tolerance; pioglitazone increased limb fat, exercise reduced limb fat - (08/09/07)   Effects of tipranavir/r in comparison with lopinavir/r on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks - (08/06/07)   Effects of alternate treatment protocols (discontinuation vs viral suppression) on the incidence of electrocardiographic abnormalities among HIV-infected adults in the SMART trial - (08/06/07)   Racial Differences in Long-Term Changes in Metabolic and Body Composition Parameters in Antiretroviral Naive Persons Initiating HAART: Results of the CPCRA 061 Metabolic Study - (08/06/07)   Zidovudine/lamivudine persistently contributes to peripheral insulin resistance by a body composition-independent mechanism demonstrated by repeated clamp studies during 2 years of first line ART with zidovudine/lamivudine/lopinavir/r - (08/06/07)   Effects of 4 weeks of atazanavir, lopinavir/ritonavir, or placebo on endothelial function and insulin sensitivity in healthy men - (07/20/07)   Relationship of body composition, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects: lipoatrophy associated with endothelial dysfunction - (07/20/07)   Lack of evidence of Metabolic Abnormalities and Mitochondrial Toxicity with Enfuvertide: a double-blind, placebo-controlled, cross-over study with random sequence assignation in healthy adult volunteers - (07/20/07)   HIV, ART & Endothelial Dysfunction - (07/20/07)   Nevirapine Increases High Density Lipoprotein-Cholesterol (HDL-C) by Stimulation of Apolipoprotein AI Synthesis - (07/19/07)   Nevirapine Hypersensitivity is Different for Treatment-Experienced - (07/19/07)   TH9507, Growth Hormone Releasing Factor - (07/19/07)